ANCA-Associated Vasculitis: A Comprehensive Clinical Review for the Modern Internist

Dr Neeraj Manikath , claude.ai

Abstract

ANCA-associated vasculitides (AAV) represent a group of life-threatening systemic disorders characterized by necrotizing inflammation of small-to-medium vessels. Despite advances in diagnostics and therapeutics, delayed recognition remains common, contributing to significant morbidity and mortality. This review synthesizes current evidence on the clinical pearls, diagnostic strategies, monitoring frameworks, and evolving management paradigms in AAV, with emphasis on practical approaches for internists and subspecialists managing these complex patients.

Introduction

The ANCA-associated vasculitides encompass three principal disorders: granulomatosis with polyangiitis (GPA, formerly Wegener's granulomatosis), microscopic polyangiitis (MPA), and eosinophilic granulomatosis with polyangiitis (EGPA, formerly Churg-Strauss syndrome). These conditions share the hallmark feature of anti-neutrophil cytoplasmic antibody (ANCA) positivity and predilection for small vessel involvement, yet present with protean manifestations that challenge even experienced clinicians.

The annual incidence of AAV ranges from 13 to 20 cases per million population, with peak onset in the sixth and seventh decades. Despite their relative rarity, AAV conditions account for disproportionate morbidity, with 5-year mortality rates of 15-25% and significant treatment-related complications. Early recognition and prompt immunosuppression are crucial, as delays beyond 6 months substantially worsen renal outcomes and overall prognosis.

Clinical Pearls in Suspecting AAV

The Art of Pattern Recognition

Pearl 1: The "Two-System Rule" When patients present with unexplained constitutional symptoms (fever, weight loss, fatigue) plus involvement of two or more organ systems—particularly the upper respiratory tract, lungs, and kidneys—AAV should immediately enter the differential diagnosis. This triad represents the classic presentation of GPA but can occur across all AAV subtypes.

Pearl 2: The Sinister Sinusitis Not all chronic sinusitis is created equal. AAV-associated sinonasal disease often presents with:

Persistent bloody nasal discharge despite multiple antibiotic courses
Progressive nasal obstruction with crusting
Saddle-nose deformity (late finding indicating cartilage destruction)
Resistance to conventional treatments including surgery

A crucial hack: In any patient over 40 with "refractory sinusitis" requiring multiple ENT interventions, measure ANCA and inflammatory markers. One study found that up to 10% of patients referred for "chronic rhinosinusitis" ultimately received an AAV diagnosis.

Pearl 3: The Pulmonary-Renal Syndrome Recognition The simultaneous occurrence of diffuse alveolar hemorrhage (hemoptysis, new pulmonary infiltrates, falling hemoglobin) and glomerulonephritis constitutes a medical emergency. While Goodpasture's disease remains in the differential, AAV—particularly MPA—is more common and should prompt immediate evaluation. The absence of hemoptysis does not exclude alveolar hemorrhage; some patients present only with dyspnea and anemia.

Oyster 4: The Hidden Renal Involvement A critical diagnostic pitfall: Patients with GPA may develop rapidly progressive glomerulonephritis (RPGN) with minimal urinary symptoms. Regular urinalysis in at-risk patients is essential. The presence of dysmorphic red blood cells, red cell casts, and sub-nephrotic proteinuria strongly suggests glomerulonephritis. Absence of edema or hypertension does not exclude significant renal disease—these are often absent in crescentic glomerulonephritis.

Distinguishing Features Among AAV Subtypes

GPA (Granulomatosis with Polyangiitis):

Upper respiratory tract involvement (sinusitis, nasal symptoms) in 90%
Pulmonary nodules or cavities (rather than pure interstitial disease)
PR3-ANCA (c-ANCA) positivity in 75-90%
Subglottic stenosis (5-15% of cases, often presenting with stridor)

MPA (Microscopic Polyangiitis):

Predominant kidney and lung involvement
Absence of granulomatous inflammation
MPO-ANCA (p-ANCA) positivity in 60-80%
More frequent pulmonary hemorrhage than GPA

EGPA (Eosinophilic Granulomatosis with Polyangiitis):

Asthma (often severe, late-onset) preceding vasculitis by years
Peripheral eosinophilia (often >1,500/μL)
Tissue eosinophilia on biopsy
Cardiac involvement (myocarditis, eosinophilic cardiomyopathy) in 15-30%
MPO-ANCA positive in only 40% of cases
Peripheral neuropathy (mononeuritis multiplex) in 70%

Hack for EGPA Recognition: The "Four A's" mnemonic—Asthma, Allergic rhinitis, Eosinophilia >10%, and ANCA (though often negative). Any patient with adult-onset asthma, eosinophilia, and extrapulmonary manifestations warrants EGPA evaluation.

Diagnostic Strategies: Beyond the Basics

Laboratory Evaluation Framework

First-Tier Testing: The initial laboratory workup when AAV is suspected should include:

Complete blood count with differential (anemia, leukocytosis, eosinophilia)
Comprehensive metabolic panel (renal function, electrolytes)
Urinalysis with microscopy (essential, not dipstick alone)
Inflammatory markers (ESR, CRP—both typically markedly elevated)
ANCA testing by both immunofluorescence and ELISA

Pearl 5: The ANCA Testing Paradigm Modern ANCA testing combines immunofluorescence patterns (c-ANCA, p-ANCA) with antigen-specific ELISA (anti-PR3, anti-MPO). Key points:

Immunofluorescence alone has approximately 30% false-positive rate
ELISA confirmation is mandatory before making treatment decisions
In active, systemic disease, sensitivity of combined testing approaches 95%
ANCA titers correlate poorly with disease activity during follow-up in many patients
ANCA-negative AAV exists (10-20% of cases, more common in limited GPA)

Oyster 6: The Atypical ANCA Pattern Atypical ANCA patterns (neither c- nor p-ANCA) or positive immunofluorescence with negative ELISA warrant caution. These findings often represent interference from other autoantibodies and should not be used to diagnose AAV without histological confirmation.

Second-Tier and Confirmatory Testing:

Anti-glomerular basement membrane (anti-GBM) antibodies if pulmonary-renal syndrome present
Complement levels (typically normal in AAV; low levels suggest alternative diagnoses)
Hepatitis B and C serologies (can cause ANCA-positive vasculitis)
Age-appropriate malignancy screening (paraneoplastic mimics)
Tissue biopsy for definitive diagnosis when feasible

Histopathological Confirmation

The Biopsy Imperative: While ANCA positivity supports the diagnosis, histological confirmation remains the gold standard, particularly when:

ANCA is negative but clinical suspicion is high
Distinguishing between AAV subtypes
Excluding mimics (infection, malignancy, drug-induced vasculitis)
Before committing patients to long-term immunosuppression

Target Organ Selection for Biopsy: The choice of biopsy site depends on clinical involvement and accessibility:

Kidney biopsy (highest yield, 80-90% sensitivity)
- Reveals necrotizing crescentic glomerulonephritis with pauci-immune deposits on immunofluorescence
- Provides prognostic information (percentage of crescents, chronicity features)
- Hack: Even with mild renal dysfunction, if urinalysis is abnormal, pursue renal biopsy early—irreversible fibrosis develops rapidly
Lung biopsy (via bronchoscopy or surgical approach)
- Transbronchial biopsy has low sensitivity (<50%); surgical biopsy preferred for nodules
- Bronchoalveolar lavage helpful in diffuse alveolar hemorrhage (progressively bloody returns, hemosiderin-laden macrophages)
Skin biopsy
- Leukocytoclastic vasculitis pattern, though not specific for AAV
- Target palpable purpura or nodular lesions
Upper respiratory tract biopsy
- Lower sensitivity (50-75%) due to sampling error and superimposed inflammation
- Multiple biopsies from different sites increase yield

Pearl 7: The Limited Disease Conundrum Limited GPA (formerly "Wegener's granulomatosis, limited form") presents without renal involvement, typically affecting upper and lower respiratory tracts. These patients may have negative ANCA and normal inflammatory markers, making diagnosis particularly challenging. Low threshold for tissue biopsy and consideration of ENT or pulmonary subspecialty referral is warranted.

Disease Severity Assessment and Risk Stratification

The European Vasculitis Study Group (EUVAS) classification system stratifies patients by disease severity, guiding treatment intensity:

Localized disease: Upper/lower respiratory tract involvement without systemic features or organ-threatening disease

Early systemic disease: Constitutional symptoms and organ involvement without organ-threatening or life-threatening manifestations (serum creatinine <150 μmol/L)

Generalized disease: Renal involvement (serum creatinine 150-500 μmol/L) or other organ-threatening disease

Severe disease: Life-threatening manifestations including renal failure (creatinine >500 μmol/L), pulmonary hemorrhage, cardiac involvement, or intestinal ischemia

Refractory disease: Progressive disease despite appropriate therapy, or relapse during immunosuppression

Hack for Severity Assessment: The Five-Factor Score (FFS), originally developed for polyarteritis nodosa but applicable to AAV, assigns one point for each:

Age >65 years
Cardiac involvement
Gastrointestinal involvement
Renal insufficiency (creatinine >150 μmol/L)
Absence of ENT symptoms

Scores ≥2 indicate worse prognosis and warrant aggressive therapy.

Contemporary Management Strategies

Induction Therapy: Achieving Remission

The goal of induction therapy is rapid disease control while minimizing treatment-related toxicity. Treatment choice depends on disease severity and patient factors.

For Severe Disease (Organ- or Life-Threatening):

The standard approach combines:

Glucocorticoids: High-dose therapy remains cornerstone
- Methylprednisolone 500-1,000 mg IV daily for 3 days for severe presentations
- Followed by oral prednisone 1 mg/kg/day (maximum 80 mg)
- Gradual taper over 5-6 months to minimize relapse risk
Rituximab vs. Cyclophosphamide: The RAVE and RITUXVAS trials demonstrated rituximab non-inferiority to cyclophosphamide, with some advantages:

Rituximab protocol:
- 375 mg/m² IV weekly for 4 weeks, OR
- 1,000 mg IV on days 1 and 15 (rheumatoid arthritis protocol, increasingly used)
- Preferred in patients desiring fertility preservation
- May be superior for relapsing disease
- Lower cumulative toxicity
Cyclophosphamide protocol:
- 15 mg/kg IV every 2 weeks for 3 doses, then every 3 weeks
- Dose reduction for age >60, renal impairment
- Duration: 3-6 months
- Mesna and antiemetics for cytoprotection
- Monthly monitoring: CBC, urinalysis, infection surveillance

Pearl 8: The Steroid-Sparing Approach Recent trials (PEXIVAS, LoVAS) suggest reduced glucocorticoid regimens may achieve similar efficacy with less toxicity. Consider reduced-dose protocols (starting at 0.5-0.75 mg/kg) in select patients, particularly elderly or those with contraindications to high-dose steroids.

Plasma Exchange: The role of therapeutic plasma exchange (TPE) has evolved following the PEXIVAS trial, which showed no overall benefit in preventing death or end-stage renal disease. However, subset analyses and clinical experience suggest TPE may benefit:

Patients with severe renal impairment (creatinine >4 mg/dL or dialysis-dependent)
Diffuse alveolar hemorrhage with respiratory failure
Patients with dual positivity (ANCA + anti-GBM antibodies)

Protocol: 7 exchanges over 14 days, replacing 60 mL/kg plasma with albumin.

For Generalized Non-Severe Disease:

Options include:

Rituximab (preferred by many experts)
Cyclophosphamide at standard or reduced doses
Methotrexate 20-25 mg weekly (for GPA without significant renal impairment; creatinine <150 μmol/L)

For Limited Disease:

Consider:

Methotrexate with moderate-dose glucocorticoids
Rituximab in select cases
Close monitoring for progression to systemic involvement

Maintenance Therapy: Preventing Relapse

Relapse rates without maintenance therapy exceed 50% at 5 years. Current maintenance strategies:

First-Line Options:

Rituximab
- 500 mg IV every 6 months for at least 24 months
- Tailored regimens based on CD19/CD20 monitoring increasingly used
- Superior to azathioprine in preventing relapses (MAINRITSAN trial)
Azathioprine
- 2 mg/kg/day (typical dose 150 mg daily)
- Check thiopurine methyltransferase (TPMT) activity before initiation
- Monitor CBC monthly initially, then every 3 months
- Less effective than rituximab but more economical
Methotrexate
- 20-25 mg weekly with folic acid supplementation
- Alternative to azathioprine, particularly in PR3-ANCA positive patients
- Contraindicated if GFR <30 mL/min

Duration of Maintenance:

Minimum 24 months after remission induction
Extended therapy (>24 months) for high-risk patients:
- Previous relapses
- PR3-ANCA positivity (higher relapse risk than MPO-ANCA)
- Pulmonary involvement
- Persistent ANCA positivity

Oyster 9: The ANCA Monitoring Controversy While intuitive to follow ANCA titers, their utility in predicting relapse remains controversial. Rising titers increase relapse probability but have poor positive predictive value (30-40%). Many relapses occur without ANCA rise, and many ANCA rises occur without clinical relapse. Current consensus: Do not escalate therapy based solely on ANCA titer changes; treat clinical disease activity.

Special Populations and Scenarios

EGPA-Specific Considerations:

Mild disease (no organ-threatening features): Glucocorticoids alone may suffice
Mepolizumab (anti-IL-5 therapy) 300 mg SC monthly approved for relapsing or refractory EGPA
Cardiac involvement requires aggressive therapy with cyclophosphamide or rituximab

Elderly Patients:

Higher infection risk with intensive immunosuppression
Consider reduced-dose glucocorticoid protocols
Careful monitoring for steroid complications (hyperglycemia, osteoporosis, psychosis)
Pneumocystis jirovecii prophylaxis (trimethoprim-sulfamethoxazole) essential

Pregnancy Considerations:

Rituximab: Crosses placenta; discontinue 6-12 months pre-conception
Cyclophosphamide: Teratogenic; absolute contraindication
Azathioprine: Generally considered safe in pregnancy
Glucocorticoids: Safe, though associated with minor increased risks

Monitoring Strategies: The Vigilant Approach

Effective AAV management requires systematic monitoring for disease activity, treatment response, and complications.

Disease Activity Assessment:

Clinical Monitoring:
- Birmingham Vasculitis Activity Score (BVAS): Validated tool quantifying disease activity across organ systems
- Symptom review: Constitutional symptoms, organ-specific complaints
- Physical examination: Blood pressure, cardiopulmonary examination, skin, neurological assessment
Laboratory Surveillance:
- Monthly during induction, then every 3 months during maintenance:
  - CBC (cytopenias from disease or treatment)
  - Comprehensive metabolic panel (renal function)
  - Urinalysis with microscopy (renal relapse often subclinical)
  - Inflammatory markers (ESR, CRP)
- ANCA titers: Every 3-6 months (interpret cautiously)
Imaging:
- Chest imaging (CT) for pulmonary involvement at baseline and with respiratory symptoms
- Sinus CT if upper respiratory symptoms persist

Pearl 10: The Urinalysis Vigilance Principle Regular urinalysis is the single most important monitoring test. Renal relapse typically precedes symptoms and substantial creatinine elevation. New or worsening hematuria, proteinuria, or cellular casts should prompt urgent nephrology consultation and potential biopsy.

Infection Surveillance:

Infections account for 50% of deaths in the first year post-diagnosis. Essential preventive measures:

Pneumocystis jirovecii pneumonia (PCP) prophylaxis: Trimethoprim-sulfamethoxazole double-strength three times weekly for all patients on >20 mg prednisone plus another immunosuppressant
Influenza and pneumococcal vaccination (preferably before immunosuppression initiation)
Screening for latent tuberculosis (IGRA or TST) before treatment
Low threshold for infectious workup when fevers occur

Hack for Infection vs. Relapse Differentiation: When patients on treatment present with new symptoms, distinguish infection from relapse:

Infection more likely: Fever, focal symptoms, bandemia, CRP elevation disproportionate to ESR
Relapse more likely: Multisystem involvement, rising ANCA, urinary abnormalities, ESR/CRP concordance

When uncertain, complete infectious workup before escalating immunosuppression.

Treatment Toxicity Monitoring:

Cyclophosphamide: CBC weekly initially, urine cytology annually (bladder cancer risk), fertility preservation counseling
Rituximab: Immunoglobulin levels (risk of hypogammaglobulinemia), hepatitis B reactivation screening
Glucocorticoids: Blood glucose, bone density, ophthalmologic examination (cataracts, glaucoma)
Azathioprine/Methotrexate: Hepatic transaminases, CBC

Relapse Management

Relapses occur in 40-50% of patients within 5 years. Approach depends on severity:

Minor Relapses (non-organ-threatening):

Increase glucocorticoids temporarily
Optimize maintenance immunosuppression
Consider switching maintenance agents

Major Relapses (organ-threatening):

Repeat induction protocol
Consider rituximab if cyclophosphamide was used initially (and vice versa)
Investigate and address potential triggers (infections, medication non-adherence)

Refractory Disease: Options include:

Alternative induction agents (switch between rituximab and cyclophosphamide)
Plasma exchange
Intravenous immunoglobulin (IVIG)
Investigational therapies (avacopan, complement inhibitors)

Emerging Therapies and Future Directions

Avacopan (C5a receptor antagonist): The ADVOCATE trial demonstrated avacopan efficacy as glucocorticoid-sparing agent, achieving FDA approval. Benefits include remission induction while reducing steroid exposure and associated toxicity. Typical dosing: 30 mg twice daily. May become standard component of induction regimens.

Other Investigational Approaches:

Abatacept (CTLA-4 inhibitor): Phase II/III trials ongoing
Tocilizumab (IL-6 inhibition): Case series suggest benefit in refractory cases
Complement inhibitors beyond avacopan
Mesenchymal stem cell therapy

Conclusion

ANCA-associated vasculitides remain diagnostic and therapeutic challenges requiring high clinical suspicion, systematic evaluation, and individualized treatment approaches. The modern internist must recognize subtle early manifestations, pursue timely diagnosis with appropriate laboratory and histological confirmation, stratify disease severity, implement evidence-based induction and maintenance strategies, and maintain vigilance for relapses and treatment complications.

Key principles for excellence in AAV management include:

Consider AAV in unexplained multisystem disease, particularly with upper respiratory, pulmonary, and renal involvement
Pursue tissue diagnosis whenever feasible before long-term immunosuppression
Tailor treatment intensity to disease severity and patient factors
Implement systematic monitoring protocols emphasizing urinalysis surveillance
Balance aggressive disease control with infection prevention
Engage multidisciplinary teams (rheumatology, nephrology, pulmonology) early
Maintain long-term vigilance for relapse

As therapeutic options expand and our understanding of disease pathogenesis deepens, outcomes continue to improve. However, the fundamentals of astute clinical recognition, thorough evaluation, judicious treatment selection, and meticulous monitoring remain the cornerstones of successful AAV management.

References

Jennette JC, Falk RJ, Bacon PA, et al. 2012 Revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum. 2013;65(1):1-11.
Stone JH, Merkel PA, Spiera R, et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med. 2010;363(3):221-232.
Jones RB, Tervaert JW, Hauser T, et al. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med. 2010;363(3):211-220.
Walsh M, Merkel PA, Peh CA, et al. Plasma exchange and glucocorticoids in severe ANCA-associated vasculitis (PEXIVAS). N Engl J Med. 2020;382(7):622-631.
Guillevin L, Pagnoux C, Karras A, et al. Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis. N Engl J Med. 2014;371(19):1771-1780.
Jayne DRW, Bruchfeld AN, Harper L, et al. Randomized trial of C5a receptor inhibitor avacopan in ANCA-associated vasculitis. J Am Soc Nephrol. 2017;28(9):2756-2767.
Yates M, Watts RA, Bajema IM, et al. EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis. Ann Rheum Dis. 2016;75(9):1583-1594.
Robson J, Doll H, Suppiah R, et al. Damage in the ANCA-associated vasculitides: long-term data from the European Vasculitis Study Group (EUVAS) therapeutic trials. Ann Rheum Dis. 2015;74(1):177-184.
Flossmann O, Berden A, de Groot K, et al. Long-term patient survival in ANCA-associated vasculitis. Ann Rheum Dis. 2011;70(3):488-494.
Finkielman JD, Lee AS, Hummel AM, et al. ANCA are detectable in nearly all patients with active severe Wegener's granulomatosis. Am J Med. 2007;120(7):643.e9-14.

Word Count: 3,012 words

Search This Blog

Internal medicine